SCHEMBL1454786

SCHEMBL1454786

[CH2]CC(C)Sc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.42
▸ MAOB P27338 1/20 0.42
▸ SLC6A4 P31645 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ L3MBTL1 Q9Y468 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ GAA P10253 1/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ MGLL Q99685 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ LMNA P02545 2/20 0.35
▸ CYP2D6 P10635 1/20 0.34
▸ MTNR1A P48039 3/20 0.34
▸ MTNR1B P49286 3/20 0.34
▸ PAX8 Q06710 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1453904 0.79 L3MBTL1 (0.45) MAOAMAOBSLC6A4ALDH1A1MAPK1
SCHEMBL1721851 0.77 MAOA (0.42) MAOAMAOBSLC6A4ALDH1A1MAPK1
SCHEMBL20449068 0.77 MAOA (0.47) MAOAMAOBSLC6A4ALDH1A1MAPK1
Fluoride SCHEMBL1335974 0.77 MAOA (0.47) MAOAMAOBSLC6A4ALDH1A1MAPK1
SCHEMBL585722 0.77 MAOA (0.42) MAOAMAOBSLC6A4ALDH1A1MAPK1
SCHEMBL9052050 0.77 TRPA1 (0.42) MAOAMAOBSLC6A4ALDH1A1MAPK1
SCHEMBL1454709 0.76 MAOA (0.41) MAOAMAOBSLC6A4ALDH1A1MAPK1
SCHEMBL8387097 0.76 MAOA (0.61) MAOAMAOBSLC6A4ALDH1A1MAPK1
SCHEMBL1452909 0.74 MAOA (0.39) MAOAMAOBSLC6A4ALDH1A1MAPK1
SCHEMBL1453376 0.73 MAOA (0.41) MAOAMAOBSLC6A4ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7910617-B2 Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound SANKYO COMPANY, LIMITED (JP) 2011-03-22 — — US disclosed
US-20070191468-A1 Amino alcohol compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2007-08-16 — — US disclosed
EP-1733724-A1 AMINO ALCOHOL COMPOUND Sankyo Company, Limited (JP) 2006-12-20 — — EP disclosed
EP-0628026-B1 CYANO-OXIME ETHERS, PROCESS FOR PRODUCING THEM, AGENTS CONTAINING THEM AND THEIR USE BASF AG (DE) 1997-01-22 — — EP disclosed
EP-0628026-A1 CYANO-OXIME ETHERS, PROCESS FOR PRODUCING THEM, AGENTS CONTAINING THEM AND THEIR USE. BASF AG (DE) 1994-12-14 — — EP disclosed
WO-1993016985-A1 CYANO-OXIME ETHERS, PROCESS FOR PRODUCING THEM, AGENTS CONTAINING THEM AND THEIR USE BASF AKTIENGESELLSCHAFT (DE) 1993-09-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191468-A1 Amino alcohol compound ADH1A, ADH1C, BCAT1 MAOA 2055/4885MAOB 1138/4885SLC6A4 1912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback